Lance Smallshaw
UCB Biopharma sprl., Belgium
Biography
Lance Smallshaw on boarded at UCB Pharma S.A. in Belgium in early 2011, after completing nearly 30 years at Eli Lilly and Company based in various locations around the world specializing in both biopharmaceutical/chemical analytical development and QC (API/Parentals). In addition to his previous role he was a corporate QC laboratory auditor and trainer in statistics and statistical process control (SPC) for more than 15 years. He has been a major industry contributor to a number of collaborative UK dti/BIUS funded new biopharmaceutical technologies initiatives. In past years for his long service was awarded a CaSSS Associated Directorship. After the publication of his UK Pharmaceutical Quality Group (PQG) CQI monograph back in 2007 on Good Quality Control Laboratory Practice (based on Eurdralex Volume 4 Chapter 6 (EU GMP Guide) he was approached the following year to become a member of the training team for the European Qualified Person Association (EQPA section of the European Compliance Academy (ECA)) and has been delivering training on a biannual basis since. As a consequence of his service to EQPA over the past 8 years and in recent years he has been appointed to the Executive Board of the European Compliance Academy (ECA), the largest Pharma training organization in Europe. He is a Fellow and Chartered Chemist (Royal Society of Chemistry (1999)) and has published widely, two of his most recent publications being accepted by Nature-biotechnology (2010) and Pharmaceutical Technology Europe March 2015. He is the UCB Pharma Global Lead for Elemental Impurities to ICH Q3D and UCB Worldwide Expert for New Biological Entities (NBEs) and analytical strategies.